Editas Medicine, Inc. (EDIT) Stock

Editas Medicine, Inc. (EDIT) is a Healthcare stock trading at $3.10 (as of 2026-08-21), with a market capitalization of $476.10M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Editas Medicine, Inc. is a clinical-stage genome editing company that uses a CRISPR-based platform to develop gene-based therapies for diseases including inherited retinal disorders and other conditions. Its pipeline includes EDIT-101 (Phase 1/2 for Leber congenital amaurosis 10) and EDIT-102 for Usher syndrome 2A, and it also develops additional oncology cell therapies and partnered research programs.

Understand Editas Medicine, Inc.: how it makes money

Editas Medicine develops CRISPR-based gene editing therapies in clinical studies, including EDIT-101 (Phase 1/2 for Leber Congenital Amaurosis 10) and EDIT-102 (for Usher Syndrome 2A), and it records collaboration and other research and development revenue.

The company’s profit model depends on collaboration and other research and development revenue, and in the latest period provided, that revenue is 0.0B, so operating results are dominated by ongoing development rather than product sales in these facts.

Revenue by segment (latest quarter)
Collab R&D	$0.0B

Business quality (Weak): Clinical-stage gene editing pipeline, with zero collaboration and other research and development revenue in the latest quarter provided and a very large operating loss implied by the operating margin.

Bull case

Sickle cell program has a reported success threshold metric, with Fetal Hemoglobin Level Threshold shown at 30.0 percent: This indicates the company tracks disease-relevant pharmacodynamic endpoints in its RUBY trial related metrics.
RUBY trial effectiveness-related metric is reported, with RUBY Patients Free of Vaso-Occlusive Events at 11.0: The company also reports longer follow-up progress, with RUBY Patients With at Least Five Months of Follow-Up at 6.0 and Mean Fetal Hemoglobin at Month 6 at 48.5 percent.

Bear case

Latest-quarter revenue shown is 0.0B for Collaboration and Other Research and Development Revenue: With zero revenue in this line item in the provided facts, operating performance is likely heavily constrained by development spending.
Operating margin for the latest period is -883.2 percent: This reflects substantial operating losses relative to revenue in the provided financial snapshot.
Clinical-study visibility in the provided facts includes limited patient counts, such as 12.0 for Leber Congenital Amaurosis 10 BRILLIANCE Study Adult Safety Update Patient Count: Smaller early-stage cohorts can make outcomes more sensitive to patient-to-patient variability.

Valuation — source: SEC EDGAR (first-party)
Price	$3.10
Market Cap	$476.10M
Price / Book	4.52
Price / Sales	18.97
FCF Yield	-48.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$40.52M
Net Margin	-395.0%
Revenue Growth (YoY)	25.4%
EPS Growth (YoY)	-37.5%
FCF Growth (YoY)	-24.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-12.94 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($22.88M)
Institutional Holders Tracked	10
Congressional Trades (recent)	2

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Gilmore O'Neill
Employees	246
Country	US
IPO Date	2016-02-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.